Template:Isosorbide dinitrate: Difference between revisions

Latest revision as of 15:00, 31 January 2014

Isosorbide dinitrate
ISORDIL^® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Description
Clinical Pharmacology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials
ClinicalTrials.gov

@@ Line 7: / Line 7: @@
 |-
 ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate dosage and administration|Dosage and Administration]]
-|-
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate dosage forms and strengths|Dosage Forms and Strengths]]
 |-
 ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate contraindications|Contraindications]]
@@ Line 17: / Line 15: @@
 |-
 ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate drug interactions|Drug Interactions]]
-|-
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate use in specific populations|Use in Specific Populations]]
 |-
 ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate overdosage|Overdosage]]
@@ Line 25: / Line 21: @@
 |-
 ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate clinical pharmacology|Clinical Pharmacology]]
-|-
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate nonclinical toxicology|Nonclinical Toxicology]]
 |-
 ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate clinical studies|Clinical Studies]]